Section of Pediatrics and Child Neuropsychiatry, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4572-4575. doi: 10.26355/eurrev_202004_21043.
The recent outbreak of SARS-CoV-2 greatly involves the resources of the global healthcare system, as it affects newborns, adults, and elders. This infection runs in three major stages: a mild cold-like illness, a moderate respiratory syndrome and a severe acute interstitial pneumonia. SARS-CoV-2 infection seems to have a more benign evolution in children. As a matter of fact, low susceptibility and minor aggressivity have been highlighted in most cases. There are currently no effective antiviral drugs treatment for the affected children. No sufficient results have been reached by the use of interferon (IFN), lopinavir/ritonavir, orbidol, and oseltamivir in the treatment of the coronaviruses infection. The aim of this short review is to highlight the differences existing between COVID-19 cases in adults and children.
新型冠状病毒（SARS-CoV-2）的爆发极大地涉及了全球医疗体系的资源，因为它会影响新生儿、成人和老年人。这种感染可分为三个主要阶段：轻度类似感冒的疾病、中度呼吸综合征和严重急性间质性肺炎。SARS-CoV-2 感染在儿童中似乎有更良性的演变。事实上，在大多数情况下，其易感性低，侵袭性小。目前，尚无有效的抗病毒药物治疗受感染的儿童。干扰素（IFN）、洛匹那韦/利托那韦、利巴韦林和奥司他韦在冠状病毒感染治疗中的应用尚未取得充分的效果。本综述的目的是强调成人和儿童 COVID-19 病例之间存在的差异。
